Results 1 to 10 of about 37,371 (257)
Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran [PDF]
Scientific ReportsDabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim +4 more
doaj +2 more sources
Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile [PDF]
Cost Effectiveness and Resource AllocationBackground Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, associated with significant morbidity, mortality, and economic burden due to thromboembolic events.
Tomás Abbot +5 more
doaj +2 more sources
Cells, 2021 Dabigatran is a novel oral anticoagulant that directly inhibits free and fibrin-bound thrombins and exerts rapid and predictable anticoagulant effects. While the use of this reagent has been associated with an increased risk of gastrointestinal bleeding,
Hiromi Kurokawa +3 more
doaj +1 more source
Pharmaceuticals, 2023 Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung +5 more
doaj +1 more source
Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding
Perspectives in Clinical Research, 2023 Background: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation.
Anitta Shaji +4 more
doaj +1 more source
Pharmacokinetics and Pharmacogenetics of Dabigatran
Рациональная фармакотерапия в кардиологии, 2021 Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists.
A. V. Savinova +4 more
doaj +1 more source
The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports [PDF]
Arhiv za farmaciju, 2020 Dabigatran is a novel oral anticoagulant preferred due to its ease of use, favorable pharmacokinetics, decreased potential for drug-drug interactions, and the lack of monitoring requirements.
Tomić Milan
doaj +1 more source
Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia
Life, 2022 Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair +5 more
doaj +1 more source
Impact of Dabigatran Treatment on Rotation Thromboelastometry
Clinical and Applied Thrombosis/Hemostasis, 2021 A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery.
Juraj Sokol MD, PhD +8 more
doaj +1 more source
Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection
Frontiers in Pharmacology, 2021 Background and Purpose: Real-world laboratory monitoring of dabigatran activity is challenging. The purpose of the present study was to demonstrate the feasibility and accuracy of finger prick sampling with dried blood spot (fpDBS) cards in measuring the
Shin-Yi Lin +7 more
doaj +1 more source